DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Renal Denervation

The story of renal denervation and its spectacular and shocking failure in 2014 is one of the more dramatic narratives in the medical device industry, and one that we at DRG Medtech have been following closely for more than 6 years. Through his ongoing blog series outlined below, Sean Messenger, Senior Manager, Cardiovascular Medtech Insights, takes you through the history of this fascinating market, provides insight on the current state of some promising technologies, and theorizes where the market is heading.

Read more on renal denervation

Renal Denervation: Will There be a Market in 5 years?

The story of renal denervation and its spectacular and shocking failure in 2014 is one of the more dramatic narratives in the medical device industry, and one that we at DRG Medtech have been following closely for more than 6 years. Through his ongoing blog series outlined below, Sean Messenger,...

A Renal Denervation Sighting

I promise I care about non-renal denervation medical devices. Really, I do. But this area is just so dynamic that it keeps drawing my attention. So be it. I was there, sitting in the main presentation hall at the Walter E Washington Convention Center, when the

Where has renal denervation gone?

Renal denervation was the single hottest topic in cardiovascular medtech for two years, the star prospect of an industry hungry for growth stories. That, however, was before negative results of the pivotal SYMPLICITY HTN-3 trial were announced in January 2014 ...

Renal denervation fails to catch fire

This morning, an announcement from Medtronic rocked one of the hottest markets in medtech: renal denervation, the device-based treatment for hypertension. Medtronic announced that the results from its SYMPLICITY HTN-3 trial failed to meet its primary efficacy ...

Everybody loves renal denervation

As we mentioned in an earlier post, renal denervation was set to be one of the biggest trends in medtech in 2012, and it hasn?t failed us. It's been a hot topic at numerous conferences this year, including the